Potential Biomarkers as Early Detection of Diabetic Cardiomyopathy
Versions
- 2021-07-30 (2)
- 2021-09-30 (1)
Downloads
Abstract: Diabetes mellitus (DM) is one of the most prevalent and burdensome among chronic disease worldwide. Its complications accelerate mortality rate within population. Diabetic cardiomyopathy (DCM) is one of diabetes macrovascular complications, which symptoms are frequently unforeseen. Advances in pathogenesis understanding DCM underlying mechanisms remain not fully perceived. Current diagnostic approach of DCM can hardly determine diabetic patients with asymptomatic cardiomyopathy. Previous studies suggested biomarkers might detect early stage DCM. There are numerous selective biomarkers representing several pathophysiological pathways, such as myocardial fibrosis, inflammatory response, cardiomyocyte apoptosis, and metabolic dysregulation in the development of diabetic heart anomaly It was also reported those biomarkers are useful for the prognostic assessment of the disease. However, not all biomarkers are cardiac specific and can be an auspicious diagnostic tool candidate. Recent studies show that there are certain biomarkers, such as microRNA, H-FABP, IGFBP7, and some other novel cardiac biomarkers were more specifically associated with the pathological mechanism of DCM. In this review, we aimed to discuss the role of several potential cardiac biomarkers as early detection in DCM that may predict future incident of DCM, and contribute to improving mortality prediction in patients with subclinical DCM.
Keywords: Biomarker; Diabetic Cardiomyopathy
Lee W-S and Kim J. 2017. Diabetic cardiomyopathy: where we are and where we are going. Korean J. Intern. Med. 32 404–21
Zhang P-Y. 2014. Cardiovascular disease in diabetes. Eur. Rev. Med. Pharmacol. Sci. 18 2205–14
Leon B M and Maddox T M. 2015. Diabetes and cardiovascular disease : Epidemiology, biological mechanisms, treatment recommendations and future research. 6 1246–58
Jia G, Hill MA and Sowers JR. 2018. Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity Circ. Res. 122 624–38
Alonso N, Moliner P and Mauricio D. 2018. Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. Adv. Exp. Med. Biol. 1067 197–217
Gilca G, Stefanescu G, Badulescu O, Tanase D, Bararu I and Ciocoiu M. 2017. Diabetic Cardiomyopathy : Current Approach and Potential Diagnostic and Therapeutic Targets 2017
Palomer X, Pizarro-Delgado J and Vázquez-Carrera M. 2018. Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets? Trends Pharmacol. Sci. 39 452–67
Jia G, DeMarco V G and Sowers J R. 2016. Insulin resistance and hyperinsulinemia in diabetic cardiomyopathy Nat. Rev. Endocrinol. 12 144
Wang Z V and Hill J A. 2015. Diabetic cardiomyopathy: catabolism driving metabolism. Circulation 131 771–3
Borghetti G, von Lewinski D, Eaton D M, Sourij H, Houser S R and Wallner M. 2018. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. Front. Physiol. 9 1514
Rijzewijk L J, van der Meer R W, Smit J W A, Diamant M, Bax J J, Hammer S., et al. 2008. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 52 1793–9
Lorenzo O, Picatoste B, Ares-Carrasco S, Ramirez E, Egido J and Tunon J. 2011. Potential role of nuclear factor kappaB in diabetic cardiomyopathy. Mediators Inflamm. 2011 652097
Palomer X, Salvado L, Barroso E and Vazquez-Carrera M. 2013. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int. J. Cardiol. 168 3160–72
Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, Greenstein A., et al. 2009. Diabetic cardiomyopathy. Clin. Sci. (Lond). 116 741–60
Richter K and Kietzmann T. 2016. Reactive oxygen species and fibrosis: further evidence of a significant liaison Cell Tissue Res. 365 591–605
Díaz-Alvarez L and Ortega E. 2017. The Many Roles of Galectin-3, a Multifaceted Molecule, in Innate Immune Responses against Pathogens Mediators Inflamm. 2017 1–10
Johannes L, Jacob R and Leffler H. 2018. Galectins at a glance J. Cell Sci. 131 jcs208884
Argüeso P and Panjwani N. 2011. Focus on Molecules: Galectin-3 Exp. Eye Res. 92 2–3
Brinchmann M F, Patel D M and Iversen M H. 2018. The Role of Galectins as Modulators of Metabolism and Inflammation Mediators Inflamm. 2018 1–11
Li P, Liu S, Lu M, Bandyopadhyay G, Oh D, Imamura T., et al. 2016. Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance Cell 167 973–984.e12
Berezin A E. 2017. Cardiac biomarkers in diabetes mellitus: New dawn for risk stratification? Diabetes Metab. Syndr. Clin. Res. Rev. 11 S201–8
De Boer R A and Van Der Velde A R. 2013. Galectin-3: A new biomarker for heart failure progression and prognosis LaboratoriumsMedizin 37 251–60
Zhong X, Qian X, Chen G and Song X. 2018. The role of galectin-3 in heart failure and cardiovascular disease Clin. Exp. Pharmacol. Physiol. 197–203
Gruson D, Ahn S, Rousseau M and Hermans M. 2014. Serum Galectin-3 Is Elevated and Related to Cardiac Biomarkers in Types 2 Diabetes J. Card. Fail. 20 S43
Yin Q S, Shi B, Dong L and Bi L. 2014. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure J. Geriatr. Cardiol. 11 79–82
Staiger H, Keuper M, Berti L, de Angelis M H and Häring H U. 2017. Fibroblast growth factor 21-metabolic role in mice and men Endocr. Rev. 38 468–88
Planavila A, Redondo-Angulo I and Villarroya F. 2015. FGF21 and Cardiac Physiopathology Front. Endocrinol. (Lausanne). 6 1–7
Itoh N, Ohta H and Konishi M. 2015. Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy Front. Endocrinol. (Lausanne). 6 1–9
Aubert G, Vega R B and Kelly D P. 2013. Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart Biochim. Biophys. Acta - Mol. Cell Res. 1833 840–7
Chen C, Meng Z, Zheng Y, Hu B and Shen E. 2018. Fibroblast growth factor 21 inhibition aggravates cardiac dysfunction in diabetic cardiomyopathy by improving lipid accumulation Exp. Ther. Med. 15 75–84
Tanajak P, Sa-Nguanmoo P, Wang X, Liang G, Li X, Jiang C., et al. 2016. Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homeostasis and structural changes in pre-diabetic rats Acta Physiol. 217 287–99
Tanajak P, Pongkan W, Chattipakorn S C and Chattipakorn N. 2018. Increased plasma FGF21 level as an early biomarker for insulin resistance and metabolic disturbance in obese insulin-resistant rats Diabetes Vasc. Dis. Res. 15 263–9
Muralidaran Y and Viswanathan P. 2015. Diabetic Cardiomyopathy : A New Perspective of Mechanistic Approach Diabetic Cardiomyopathy : A New Perspective of Mechanistic Approach
Luo Y and Lu W. 2018. Serum Levels of FGF21 and Prediction of Cardiovascular Events Cardiol. 139 219–21
Yang H, Feng A, Lin S, Yu L, Lin X, Yan X., et al. 2018. Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart article /13/2 /13/95 /64/60 /96/95 Cell Death Dis. 9
Zhang C, Huang Z, Gu J, Yan X, Lu X, Zhou S., et al. 2015. Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signaling pathway Diabetologia 58 1937–48
Wu F, Wang B, Zhang S, Shi L, Wang Y, Xiong R., et al. 2017. FGF21 ameliorates diabetic cardiomyopathy by activating the AMPK-paraoxonase 1 signaling axis in mice Clin. Sci. 131 1877–93
Ong K L, Januszewski A S, O'Connell R, Jenkins A J, Xu A, Sullivan D R., et al. 2015. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study Diabetologia 58 464–73
Elhini S, Matta R, Saad M, Mostafa H and AbedelfadeeL A. 2017. Fibroblast growth factor-21 is a novel linkage between metabolic parameters, cardiovascular risk, and nephropathy in prediabetes Egypt. J. Obesity, Diabetes Endocrinol. 3 22–31
Beysel S, Kizilgul M, Ozbek M, Caliskan M, Kan S, Apaydin M., et al. 2017. Heart-type fatty acid binding protein levels in elderly diabetics without known cardiovascular disease Clin. Interv. Aging 12 2063
Schoenenberger A W, Stallone F, Walz B, Bergner M, Twerenbold R, Reichlin T., et al. 2016. Incremental value of heart-type fatty acid-binding protein in suspected acute myocardial infarction early after symptom onset Eur. Hear. J. Acute Cardiovasc. Care 5 185–92
Viswanathan K, Kilcullen N, Morrell C, Thistlethwaite S J, Sivananthan M U, Hassan T B., et al. 2010. Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative J. Am. Coll. Cardiol. 55 2590–8
Haltern G, Peiniger S, Bufe A, Reiss G, Gülker H and Scheffold T. 2010. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction Am. J. Cardiol. 105 1–9
Karbek B, Özbek M, Bozkurt N C, Ginis Z, Güngünes A, Ünsal Ä° Ö., et al. 2011. Heart-Type Fatty Acid Binding Protein (H-FABP): Relationship with arterial ıntima-media thickness and role as diagnostic marker for atherosclerosis in patients with ımpaired glucose metabolism Cardiovasc. Diabetol. 10 37
Shearer J, Fueger P T, Wang Z, Bracy D P, Wasserman D H and Rottman J N. 2008. Metabolic implications of reduced heart-type fatty acid binding protein in insulin resistant cardiac muscle Biochim. Biophys. Acta (BBA)-Molecular Basis Dis. 1782 586–92
Akbal E, Özbek M, Güneş F, Akyürek Ö, Üreten K and Delibaşı T. 2009. Serum heart type fatty acid binding protein levels in metabolic syndrome Endocrine 36 433–7
Komamura K, Sasaki T, Hanatani A, Kim J, Hashimura K, Ishida Y., et al. 2006. Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy Heart 92 615–8
Goto T, Takase H, Toriyama T, Sugiura T, Sato K, Ueda R., et al. 2003. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure Heart 89 1303–7
Shaver A, Nichols A, Thompson E, Mallick A, Payne K, Jones C., et al. 2016. Role of serum biomarkers in early detection of diabetic cardiomyopathy in the West Virginian population Int. J. Med. Sci. 13 161
Liu Y, Wu M, Ling J, Cai L, Zhang D, Gu H F., et al. 2015. Serum IGFBP7 levels associate with insulin resistance and the risk of metabolic syndrome in a Chinese population Sci. Rep. 5 10227
Fakhruddin S, Alanazi W and Jackson K E. 2017. Diabetes-induced reactive oxygen species: mechanism of their generation and role in renal injury J. Diabetes Res. 2017
Lorenzo-Almoros A, Tunon J, Orejas M, Cortés M, Egido J and Lorenzo í“. 2017. Diagnostic approaches for diabetic cardiomyopathy Cardiovasc. Diabetol. 16 28
Guo X H, Liu L X, Zhang H Y, Zhang Q Q, Li Y, Tian X X., 2014. Insulin"like growth factor binding protein"related protein 1 contributes to hepatic fibrogenesis J. Dig. Dis. 15 202–10
Gandhi P U, Gaggin H K, Sheftel A D, Belcher A M, Weiner R B, Baggish A L., et al. 2014. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function? Am. J. Cardiol. 114 1543–9
Januzzi Jr J L, Packer M, Claggett B, Liu J, Shah A M, Zile M R., et al. 2018. IGFBP7 (Insulin-Like Growth Factor–Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure Circ. Hear. Fail. 11 e005133
Liu P, Sun M and Sader S. 2006. Matrix metalloproteinases in cardiovascular disease Can. J. Cardiol. 22 25B–30B
Sun M, Dawood F, Wen W-H, Chen M, Dixon I, Kirshenbaum L A., et al. 2004. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction Circulation 110 3221–8
Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N., et al. 2008. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy Basic Res. Cardiol. 103 319–27
Li Q, Sun S, Wang Y, Tian Y and Liu M. 2007. The roles of MMP-2/TIMP-2 in extracellular matrix remodeling in the hearts of STZ-induced diabetic rats Acta Cardiol. 62 485–91
Ban C R, Twigg S M, Franjic B, Brooks B A, Celermajer D, Yue D K., et al. 2010. Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction Diabetes Res. Clin. Pract. 87 335–41
Münch J, Avanesov M, Bannas P, Säring D, Krämer E, Mearini G., et al. 2016. Serum matrix metalloproteinases as quantitative biomarkers for myocardial fibrosis and sudden cardiac death risk stratification in patients with hypertrophic cardiomyopathy J. Card. Fail. 22 845–50
Condorelli G, Latronico M V G and Dorn G W 2nd. 2010. microRNAs in heart disease: putative novel therapeutic targets? Eur. Heart J. 31 649–58
Condorelli G, Latronico M V G and Cavarretta E. 2014. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J. Am. Coll. Cardiol. 63 2177–87
Saraiya A A, Li W and Wang C C. 2013. Transition of a microRNA from repressing to activating translation depending on the extent of base pairing with the target. PLoS One 8 e55672
Voelter-Mahlknecht S. 2016. Epigenetic associations in relation to cardiovascular prevention and therapeutics Clin. Epigenetics 8 4
Zhou Q, Lv D, Chen P, Xu T, Fu S, Li J., et al. 2014. MicroRNAs in diabetic cardiomyopathy and clinical perspectives. Front. Genet. 5 185
Latronico M V G, Elia L, Condorelli G and Catalucci D. 2008. Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment. Int. J. Biochem. Cell Biol. 40 1643–8
Rao P K, Toyama Y, Chiang H R, Gupta S, Bauer M, Medvid R., et al. 2009. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ. Res. 105 585–94
Melman Y F, Shah R and Das S. 2014. MicroRNAs in heart failure: is the picture becoming less miRky? Circ. Heart Fail. 7 203–14
Das S, Ferlito M, Kent O A, Fox-Talbot K, Wang R, Liu D., et al. 2012. Nuclear miRNA regulates the mitochondrial genome in the heart. Circ. Res. 110 1596–603
Wang J and Yang X. 2012. The function of miRNA in cardiac hypertrophy. Cell. Mol. Life Sci. 69 3561–70
Feng B, Chen S, George B, Feng Q and Chakrabarti S. 2010. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes. Metab. Res. Rev. 26 40–9
Ruiz M A and Chakrabarti S. 2013. MicroRNAs: the underlying mediators of pathogenetic processes in vascular complications of diabetes. Can. J. diabetes 37 339–44
Jacobs L H, van de Kerkhof J J, Mingels A M, Passos V L, Kleijnen V W, Mazairac A H., et al. 2009. Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study Nephrol. Dial. Transplant. 25 243–8
Li X, Du N, Zhang Q, Li J, Chen X, Liu X., et al. 2014. MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. Cell Death Dis. 5 e1479
Shen E, Diao X, Wang X, Chen R and Hu B. 2011. MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. Am. J. Pathol. 179 639–50
Tijsen A J, Pinto Y M and Creemers E E. 2012. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol. 303 H1085-95
Jeyabal P, Thandavarayan R A, Joladarashi D, Suresh Babu S, Krishnamurthy S, Bhimaraj A., et al. 2016. MicroRNA-9 inhibits hyperglycemia-induced pyroptosis in human ventricular cardiomyocytes by targeting ELAVL1. Biochem. Biophys. Res. Commun. 471 423–9
Arnold N, Koppula P R, Gul R, Luck C and Pulakat L. 2014. Regulation of cardiac expression of the diabetic marker microRNA miR-29. PLoS One 9 e103284
Yue Y, Meng K, Pu Y and Zhang X. 2017. Transforming growth factor beta (TGF-beta) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res. Clin. Pract. 133 124–30
Liu R-M and Desai L P. 2015. Reciprocal regulation of TGF-beta and reactive oxygen species: A perverse cycle for fibrosis. Redox Biol. 6 565–77
Biernacka A, Dobaczewski M and Frangogiannis N G. 2011. TGF-beta signaling in fibrosis. Growth Factors 29 196–202
Morikawa M, Derynck R and Miyazono K. 2016. TGF-beta and the TGF-beta Family: Context-Dependent Roles in Cell and Tissue Physiology. Cold Spring Harb. Perspect. Biol. 8
Cheng R, Dang R, Zhou Y, Ding M and Hua H. 2017. MicroRNA-98 inhibits TGF-beta1-induced differentiation and collagen production of cardiac fibroblasts by targeting TGFBR1. Hum. Cell 30 192–200
Budi E H, Muthusamy B-P and Derynck R. 2015. The insulin response integrates increased TGF-beta signaling through Akt-induced enhancement of cell surface delivery of TGF-beta receptors. Sci. Signal. 8 ra96
Redza-Dutordoir M and Averill-Bates D A. 2016. Activation of apoptosis signaling pathways by reactive oxygen species. Biochim. Biophys. Acta 1863 2977–92
- Cardiovascular and Cardiometabolic Journal (CCJ) is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
-
Authors who publish with Cardiovascular and Cardiometabolic Journal (CCJ) agree to the following terms:
-
The journal allows the author to hold the copyright of the article without restrictions.
-
The journal allows the author(s) to retain publishing rights without restrictions.
-
The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution ShareAlike 4.0 International License (CC BY-SA).
